Citigroup Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $35
Seaport Therapeutics
Seaport Therapeutics SPTX | 0.00 |
Citigroup analyst Yigal Nochomovitz initiates coverage on Seaport Therapeutics (NASDAQ:
SPTX) with a Buy rating and announces Price Target of $35.
